Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy
Claire Patterson et al. present the design and development of AZD0466, a drug-dendrimer conjugate, and use preclinical and mathematical models to determine the optimal release rate of the drug from the dendrimer carrier for maximal therapeutic index in terms of anti-tumour efficacy and cardiovascula...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/722de1f4d6464ec9a94bce51fe4fc356 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:722de1f4d6464ec9a94bce51fe4fc356 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:722de1f4d6464ec9a94bce51fe4fc3562021-12-02T13:23:49ZDesign and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy10.1038/s42003-020-01631-82399-3642https://doaj.org/article/722de1f4d6464ec9a94bce51fe4fc3562021-01-01T00:00:00Zhttps://doi.org/10.1038/s42003-020-01631-8https://doaj.org/toc/2399-3642Claire Patterson et al. present the design and development of AZD0466, a drug-dendrimer conjugate, and use preclinical and mathematical models to determine the optimal release rate of the drug from the dendrimer carrier for maximal therapeutic index in terms of anti-tumour efficacy and cardiovascular tolerability. This study identifies this promising dual Bcl-2/Bcl-xL inhibitor for progression to clinical development.Claire M. PattersonSrividya B. BalachanderIain GrantPetar Pop-DamkovBrian KellyWilliam McCoullJeremy ParkerMichael GiannisKathryn J. HillFrancis D. GibbonsEdward J. HennessyPaul KemmittAlexander R. HarmerSonya GalesStuart PurbrickSean RedmondMatthew SkinnerLorraine GrahamJ. Paul SecristAlwin G. SchullerShenghua WenAmmar AdamCorinne ReimerJustin CidadoMartin WildEric GanglStephen E. FawellJamal SaehBarry R. DaviesDavid J. OwenMarianne B. AshfordNature PortfolioarticleBiology (General)QH301-705.5ENCommunications Biology, Vol 4, Iss 1, Pp 1-14 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Biology (General) QH301-705.5 |
| spellingShingle |
Biology (General) QH301-705.5 Claire M. Patterson Srividya B. Balachander Iain Grant Petar Pop-Damkov Brian Kelly William McCoull Jeremy Parker Michael Giannis Kathryn J. Hill Francis D. Gibbons Edward J. Hennessy Paul Kemmitt Alexander R. Harmer Sonya Gales Stuart Purbrick Sean Redmond Matthew Skinner Lorraine Graham J. Paul Secrist Alwin G. Schuller Shenghua Wen Ammar Adam Corinne Reimer Justin Cidado Martin Wild Eric Gangl Stephen E. Fawell Jamal Saeh Barry R. Davies David J. Owen Marianne B. Ashford Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy |
| description |
Claire Patterson et al. present the design and development of AZD0466, a drug-dendrimer conjugate, and use preclinical and mathematical models to determine the optimal release rate of the drug from the dendrimer carrier for maximal therapeutic index in terms of anti-tumour efficacy and cardiovascular tolerability. This study identifies this promising dual Bcl-2/Bcl-xL inhibitor for progression to clinical development. |
| format |
article |
| author |
Claire M. Patterson Srividya B. Balachander Iain Grant Petar Pop-Damkov Brian Kelly William McCoull Jeremy Parker Michael Giannis Kathryn J. Hill Francis D. Gibbons Edward J. Hennessy Paul Kemmitt Alexander R. Harmer Sonya Gales Stuart Purbrick Sean Redmond Matthew Skinner Lorraine Graham J. Paul Secrist Alwin G. Schuller Shenghua Wen Ammar Adam Corinne Reimer Justin Cidado Martin Wild Eric Gangl Stephen E. Fawell Jamal Saeh Barry R. Davies David J. Owen Marianne B. Ashford |
| author_facet |
Claire M. Patterson Srividya B. Balachander Iain Grant Petar Pop-Damkov Brian Kelly William McCoull Jeremy Parker Michael Giannis Kathryn J. Hill Francis D. Gibbons Edward J. Hennessy Paul Kemmitt Alexander R. Harmer Sonya Gales Stuart Purbrick Sean Redmond Matthew Skinner Lorraine Graham J. Paul Secrist Alwin G. Schuller Shenghua Wen Ammar Adam Corinne Reimer Justin Cidado Martin Wild Eric Gangl Stephen E. Fawell Jamal Saeh Barry R. Davies David J. Owen Marianne B. Ashford |
| author_sort |
Claire M. Patterson |
| title |
Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy |
| title_short |
Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy |
| title_full |
Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy |
| title_fullStr |
Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy |
| title_full_unstemmed |
Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy |
| title_sort |
design and optimisation of dendrimer-conjugated bcl-2/xl inhibitor, azd0466, with improved therapeutic index for cancer therapy |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/722de1f4d6464ec9a94bce51fe4fc356 |
| work_keys_str_mv |
AT clairempatterson designandoptimisationofdendrimerconjugatedbcl2xlinhibitorazd0466withimprovedtherapeuticindexforcancertherapy AT srividyabbalachander designandoptimisationofdendrimerconjugatedbcl2xlinhibitorazd0466withimprovedtherapeuticindexforcancertherapy AT iaingrant designandoptimisationofdendrimerconjugatedbcl2xlinhibitorazd0466withimprovedtherapeuticindexforcancertherapy AT petarpopdamkov designandoptimisationofdendrimerconjugatedbcl2xlinhibitorazd0466withimprovedtherapeuticindexforcancertherapy AT briankelly designandoptimisationofdendrimerconjugatedbcl2xlinhibitorazd0466withimprovedtherapeuticindexforcancertherapy AT williammccoull designandoptimisationofdendrimerconjugatedbcl2xlinhibitorazd0466withimprovedtherapeuticindexforcancertherapy AT jeremyparker designandoptimisationofdendrimerconjugatedbcl2xlinhibitorazd0466withimprovedtherapeuticindexforcancertherapy AT michaelgiannis designandoptimisationofdendrimerconjugatedbcl2xlinhibitorazd0466withimprovedtherapeuticindexforcancertherapy AT kathrynjhill designandoptimisationofdendrimerconjugatedbcl2xlinhibitorazd0466withimprovedtherapeuticindexforcancertherapy AT francisdgibbons designandoptimisationofdendrimerconjugatedbcl2xlinhibitorazd0466withimprovedtherapeuticindexforcancertherapy AT edwardjhennessy designandoptimisationofdendrimerconjugatedbcl2xlinhibitorazd0466withimprovedtherapeuticindexforcancertherapy AT paulkemmitt designandoptimisationofdendrimerconjugatedbcl2xlinhibitorazd0466withimprovedtherapeuticindexforcancertherapy AT alexanderrharmer designandoptimisationofdendrimerconjugatedbcl2xlinhibitorazd0466withimprovedtherapeuticindexforcancertherapy AT sonyagales designandoptimisationofdendrimerconjugatedbcl2xlinhibitorazd0466withimprovedtherapeuticindexforcancertherapy AT stuartpurbrick designandoptimisationofdendrimerconjugatedbcl2xlinhibitorazd0466withimprovedtherapeuticindexforcancertherapy AT seanredmond designandoptimisationofdendrimerconjugatedbcl2xlinhibitorazd0466withimprovedtherapeuticindexforcancertherapy AT matthewskinner designandoptimisationofdendrimerconjugatedbcl2xlinhibitorazd0466withimprovedtherapeuticindexforcancertherapy AT lorrainegraham designandoptimisationofdendrimerconjugatedbcl2xlinhibitorazd0466withimprovedtherapeuticindexforcancertherapy AT jpaulsecrist designandoptimisationofdendrimerconjugatedbcl2xlinhibitorazd0466withimprovedtherapeuticindexforcancertherapy AT alwingschuller designandoptimisationofdendrimerconjugatedbcl2xlinhibitorazd0466withimprovedtherapeuticindexforcancertherapy AT shenghuawen designandoptimisationofdendrimerconjugatedbcl2xlinhibitorazd0466withimprovedtherapeuticindexforcancertherapy AT ammaradam designandoptimisationofdendrimerconjugatedbcl2xlinhibitorazd0466withimprovedtherapeuticindexforcancertherapy AT corinnereimer designandoptimisationofdendrimerconjugatedbcl2xlinhibitorazd0466withimprovedtherapeuticindexforcancertherapy AT justincidado designandoptimisationofdendrimerconjugatedbcl2xlinhibitorazd0466withimprovedtherapeuticindexforcancertherapy AT martinwild designandoptimisationofdendrimerconjugatedbcl2xlinhibitorazd0466withimprovedtherapeuticindexforcancertherapy AT ericgangl designandoptimisationofdendrimerconjugatedbcl2xlinhibitorazd0466withimprovedtherapeuticindexforcancertherapy AT stephenefawell designandoptimisationofdendrimerconjugatedbcl2xlinhibitorazd0466withimprovedtherapeuticindexforcancertherapy AT jamalsaeh designandoptimisationofdendrimerconjugatedbcl2xlinhibitorazd0466withimprovedtherapeuticindexforcancertherapy AT barryrdavies designandoptimisationofdendrimerconjugatedbcl2xlinhibitorazd0466withimprovedtherapeuticindexforcancertherapy AT davidjowen designandoptimisationofdendrimerconjugatedbcl2xlinhibitorazd0466withimprovedtherapeuticindexforcancertherapy AT mariannebashford designandoptimisationofdendrimerconjugatedbcl2xlinhibitorazd0466withimprovedtherapeuticindexforcancertherapy |
| _version_ |
1718393157878546432 |